InvestorsHub Logo
Followers 43
Posts 2488
Boards Moderated 0
Alias Born 10/19/2015

Re: XenaLives post# 283746

Tuesday, 11/17/2020 3:23:20 PM

Tuesday, November 17, 2020 3:23:20 PM

Post# of 462242
Anavex had nothing to do with this decision. The cost of running a trial during a pandemic was not worth the profit potential of a Rett drug. As the memo said, the data was blinded and had no bearing on the decision to end the trial. Profitability matters more.

It's good news for Anavex and its shareholders but terrible news for the Rett community because there's no guarantee either of the two remaining candidates will receive FDA approval, though both look promising.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News